Calcium Acetate Reduces Serum Phosphorus in CKD Patients
Author Information
Author(s): Wajeh Qunibi, Wolfgang C Winkelmayer, Richard Solomon, Moustafa Moustafa, Paul Kessler, Chiang-Hong Ho, Jonathan Greenberg, Jose A Diaz-Buxo
Primary Institution: University of Texas Health Sciences Center
Hypothesis
Calcium acetate would safely improve phosphorus control in patients with advanced chronic kidney disease compared with placebo.
Conclusion
Calcium acetate was effective in reducing serum phosphorus and iPTH levels in CKD patients not yet on dialysis over a 12-week period.
Supporting Evidence
- Calcium acetate reduced serum phosphorus concentration from 5.1 mg/dL to 4.4 mg/dL.
- iPTH levels decreased significantly from 351 pg/mL in placebo to 150 pg/mL in calcium acetate group.
- 59.5% of patients in the calcium acetate group achieved target phosphorus levels compared to 36.6% in the placebo group.
Takeaway
This study found that a medicine called calcium acetate helps lower phosphorus levels in people with kidney disease who are not on dialysis.
Methodology
The study was a randomized, double-blind, placebo-controlled trial involving 110 nondialyzed patients with advanced CKD over 12 weeks.
Potential Biases
Randomization errors and imbalance in the number of subjects in treatment groups may introduce bias.
Limitations
The study had a dropout rate and did not measure urinary phosphorus excretion.
Participant Demographics
Participants were adults with advanced CKD, with a mean age of approximately 63 years, and included both genders.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website